Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | MGMT | P16455 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | TPO | P07202 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | EPX | P11678 | 1/20 | 0.47 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28159223 | 0.87 | NUDT1 (0.47) | NUDT1LTA4HMAPK14ROCK1HRH4 | |
| SCHEMBL2749680 | 0.84 | NUDT1 (0.51) | NUDT1ROCK1MAOB | |
| SCHEMBL1163924 | 0.80 | ALKBH1 (0.47) | NUDT1LTA4HMAPK14CYP3A4ALKBH1 | |
| SCHEMBL4271456 | 0.80 | ALKBH1 (0.47) | NUDT1LTA4HMAPK14CYP3A4ALKBH1 | |
| SCHEMBL753735 | 0.79 | L3MBTL1 (0.47) | NUDT1LTA4HMAPK14ALKBH1L3MBTL1 | |
| SCHEMBL26985597 | 0.79 | ALKBH1 (0.46) | NUDT1LTA4HMAPK14CYP3A4ALKBH1 | |
| Methane SCHEMBL7252421 | 0.79 | ALKBH1 (0.46) | NUDT1LTA4HMAPK14CYP3A4ALKBH1 | |
| SCHEMBL2524154 | 0.78 | L3MBTL1 (0.52) | NUDT1L3MBTL1GAAMAPTMAOA | |
| SCHEMBL25517357 | 0.78 | NUDT1 (0.44) | NUDT1LTA4HMAPK14ALKBH1L3MBTL1 | |
| SCHEMBL6266136 | 0.77 | NUDT1 (0.66) | NUDT1LTA4HMAPK14HRH4MGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313554-A1 | PTPN2 INHIBITORS | MONDEGO BIO, LDA. (PT) | 2025-10-09 | — | — | US | disclosed |
| EP-4522594-A1 | PTPN2 INHIBITORS | Ness Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119522216-A | PTPN2 inhibitors | 尼斯治疗公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2023220572-A1 | PTPN2 INHIBITORS | NESS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20140023592-A1 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | RWTH AACHEN (DE) | 2014-01-23 | — | — | US | disclosed |
| EP-2587263-A1 | Self coupling recombinant antibody fusion proteins | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-2049499-B1 | LABELLING OF FUSION PROTEINS WITH SYNTHETIC PROBES | EPFL ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2012-10-31 | — | — | EP | disclosed |
| CN-101679309-B | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2012-02-29 | — | — | CN | disclosed |
| US-20110014196-A1 | Drug Transfer into Living Cells | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| CN-101828113-A | Self-binding recombinant antibody fusion proteins | FRAUNHOFER GES FORSCHUNG | 2010-09-08 | — | — | CN | disclosed |
| US-20100183516-A1 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2171456-A2 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2010-04-07 | — | — | EP | disclosed |
| CN-101679309-A | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| WO-2009043899-A1 | DRUG TRANSFER INTO LIVING CELLS | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009013359-A2 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | FRAUNHOFER GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014196-A1 | Drug Transfer into Living Cells | TSPO, MPI, ABCB1 | NUDT1 576/4885LTA4H 3142/4885MAPK14 4197/4885 |
| US-20250313554-A1 | PTPN2 INHIBITORS | PTPN2, PTPN1, PTPRJ | NUDT1 2662/4885LTA4H 3409/4885MAPK14 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.